Rowe Heather Armstrong
Directeur/Membre du Conseil chez National Investor Relations Institute /Los Angeles/
Profil
Rowe Heather Armstrong is currently the Director at the National Investor Relations Institute (Rocky Mountain), the Director at the National Investor Relations Institute, and a Member at the National Investor Relations Institute.
Previously, she held positions such as Senior Director-Corporate Communications & IR at Five Prime Therapeutics, Director-Investor Relations at Kythera Biopharmaceuticals LLC, and VP-Corporate Communications & IR at Dynavax Technologies Corp.
She was also the Investor Relations Contact at AeroVironment, Inc. from 2009 to 2011 and the Vice President-Investor Relations at Vir Biotechnology, Inc. Additionally, she was the VP-Corporate Communications & Investor Relations at Arcutis Biotherapeutics, Inc. from 2020 to 2021.
Armstrong received a graduate degree from Texas Tech University and an undergraduate degree from New Mexico State University.
Postes actifs de Rowe Heather Armstrong
| Sociétés | Poste | Début |
|---|---|---|
National Investor Relations Institute
 National Investor Relations Institute Miscellaneous Commercial ServicesCommercial Services National Investor Relations Institute operates as an association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents. The company was founded by DeWitt C. Morrill in 1969 and is headquartered in Alexandria, VA. | Corporate Officer/Principal | - |
National Investor Relations Institute (Rocky Mountain)
 National Investor Relations Institute (Rocky Mountain) Miscellaneous Commercial ServicesCommercial Services National Investor Relations Institute engages in IR consultants and related services. The company was founded in 1969 and is headquartered in Denver, CO. | Directeur/Membre du Conseil | - |
| National Investor Relations Institute /Los Angeles/ | Directeur/Membre du Conseil | - |
Anciens postes connus de Rowe Heather Armstrong
| Sociétés | Poste | Fin |
|---|---|---|
| VIR BIOTECHNOLOGY, INC. | Investor Relations Contact | 01/10/2022 |
| ARCUTIS BIOTHERAPEUTICS, INC. | Investor Relations Contact | 02/08/2021 |
| AEROVIRONMENT, INC. | Public Communications Contact | 01/11/2011 |
| KYTHERA BIOPHARMACEUTICALS INC | Investor Relations Contact | - |
| FIVE PRIME THERAPEUTICS, INC. | Investor Relations Contact | - |
Formation de Rowe Heather Armstrong
| Texas Tech University | Graduate Degree |
| New Mexico State University | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| AEROVIRONMENT, INC. | Electronic Technology |
| VIR BIOTECHNOLOGY, INC. | Health Technology |
| ARCUTIS BIOTHERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Kythera Biopharmaceuticals LLC
 Kythera Biopharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Kythera Biopharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel prescription products for the aesthetic medicine market. The company was founded by Jay Edward Birnbaum, Amit D. Munshi, Nathaniel Eames David, and Keith R. Leonard, Jr. on June 3, 2004 and is headquartered in Westlake, CA. | Health Technology |
National Investor Relations Institute
National Investor Relations Institute Miscellaneous Commercial ServicesCommercial Services National Investor Relations Institute operates as an association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents. The company was founded by DeWitt C. Morrill in 1969 and is headquartered in Alexandria, VA. | Commercial Services |
National Investor Relations Institute (Rocky Mountain)
National Investor Relations Institute (Rocky Mountain) Miscellaneous Commercial ServicesCommercial Services National Investor Relations Institute engages in IR consultants and related services. The company was founded in 1969 and is headquartered in Denver, CO. | Commercial Services |
| National Investor Relations Institute /Los Angeles/ |